Drug Patent Watch
DECEMBER 31, 2023
TASIGNA (nilotinib hydrochloride) Novartis Patent: 7,169,791 Expiration: Jan 4, 2024 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or… The post Drug Patent Expirations for the Week of December 31, 2023 appeared first on DrugPatentWatch - Make Better Decisions.
Perficient: Drug Development
DECEMBER 31, 2023
In our upcoming installment, we set our sights on a crucial aspect of empowerment for individuals with multiple or compound disabilities – Mobility Aids. Join us on this exploration as we delve into the diverse range of assistive devices designed to enhance mobility, foster independence, and break down barriers for those navigating the complexities of multiple disabilities.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
DECEMBER 31, 2023
Annual Drug Patent Expirations for LEQVIO Leqvio is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are seventeen patents protecting… The post New patent expiration for Novartis drug LEQVIO appeared first on DrugPatentWatch - Make Better Decisions.
Perficient: Drug Development
DECEMBER 31, 2023
In our upcoming installment, we embark on a profound exploration of a transformative mobility aid – Manual Wheelchairs. Join us as we delve into the intricacies of these versatile devices designed to empower individuals facing the complexities of multiple or compound disabilities. From customization to ergonomic design, we unravel the dynamics that make manual wheelchairs a key player in enhancing independence, mobility, and overall quality of life.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Patent Watch
DECEMBER 31, 2023
Annual Drug Patent Expirations for GIVLAARI Givlaari is a drug marketed by Alnylam Pharms Inc and is included in one NDA. It is available from one supplier. There are thirteen… The post New patent expiration for Alnylam Pharms drug GIVLAARI appeared first on DrugPatentWatch - Make Better Decisions.
Perficient: Drug Development
DECEMBER 31, 2023
In our fast-paced digital age, where smartphones have become an extension of ourselves, technology is increasingly playing a vital role in shaping our well-being. For those grappling with psychological and psychiatric disabilities, the journey towards mental health has found an ally in the form of innovative apps. In this installment, we set our sights on “ Moodpath ,” a beacon of support for those navigating the intricate landscapes of mental health.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Perficient: Drug Development
DECEMBER 31, 2023
In the ever-evolving landscape of mental health support, mobile applications are emerging as transformative tools, offering solace and guidance to individuals navigating psychological and psychiatric disabilities. In our upcoming installment, we will embark on an insightful journey into the realms of “Youper,” a beacon of hope and assistance in the intricate tapestry of mental well-being.
Molecular Design
DECEMBER 31, 2023
One piece of general advice that I offer to fellow scientists is to not let the fact that an article has been published in Nature (or any other ‘elite’ journal for that matter) cause you to switch off your critical thinking skills while reading it and the BW2014 article (Chemistry: Chemical con artists foil drug discovery) that I’ll be reviewing in this post is an excellent case in point.
Perficient: Drug Development
DECEMBER 31, 2023
In the mosaic of diverse abilities and challenges, individuals with multiple or compound disabilities often find themselves at the intersection of various support needs. In our forthcoming installment, we embark on a journey through the landscape of assistive technologies and adaptive strategies tailored to address the complexities of multiple disabilities.
Perficient: Drug Development
DECEMBER 31, 2023
In part 1 we covered some fundamentals of Next.js – rendering strategies along with the nuances of getStaticProps, getStaticPaths, getServerSideProps as well as data fetching. Now we are going to talk about UI-related things, such as layouts, styles and fonts, serving statics, as well as typescript and environmental variables. Built-in CSS support Importing global styles To add global styles, the corresponding table must be imported into the pages/_app.js file ( pay attention to the unders
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Perficient: Drug Development
DECEMBER 31, 2023
In our upcoming installment, we dive into the transformative world of Communication Devices, a crucial aspect of Mobility Aids designed for individuals facing the intricate challenges of multiple or compound disabilities. Join us as we explore the innovative technologies that empower users to express themselves, connect with others, and break down communication barriers on their journey to independence.
Expert insights. Personalized for you.
59 
Let's personalize your content